Hester''s Corporate Presentation for FY 2025-26
HESTERBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Hester Biosciences has released its FY 2025-26 corporate presentation, showcasing its position as Asia's largest animal vaccine producer with operations across India, Nepal, and Africa. The company reported consolidated revenue of Rs 332.60 crore with profit after tax of Rs 57.48 crore for FY 2025-26, representing strong recovery from Rs 21.17 crore PAT in FY 2024-25. The business is split between Poultry Healthcare (62%) and Animal Healthcare (38%) on a consolidated basis. Key highlights include being the world's largest supplier of PPR vaccine, second largest poultry vaccine manufacturer in India with 35% market share, and largest supplier of LSD vaccine to African countries. The company operates 3 manufacturing plants with a combined capacity of over 11 billion doses annually and has a presence in 35+ countries.
The presentation demonstrates strong financial recovery with PAT more than doubling year-on-year, though it lacks specific forward-looking guidance or margin targets for investors to assess future performance expectations.